2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16500R
    Tolrestat (Standard)
    		Inhibitor
    Tolrestat (Standard) is the analytical standard of Tolrestat. This product is intended for research and analytical applications. Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
    Tolrestat (Standard)
  • HY-N14419
    Salfredin C3
    		Inhibitor
    Salfredin C3 is an aldose reductase inhibitor.
    Salfredin C3
  • HY-N14449
    Salfredin A4
    		Inhibitor
    Salfredin A4 is an aldose reductase inhibitor.
    Salfredin A4
  • HY-N0309R
    Soyasaponin Ba (Standard)
    		Inhibitor
    Soyasaponin Ba (Standard) is the analytical standard of Soyasaponin Ba. This product is intended for research and analytical applications. Soyasaponin Ba is a soyasaponin isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitors (ARI).
    Soyasaponin Ba (Standard)
  • HY-16255R
    Imirestat (Standard)
    		Inhibitor
    Imirestat (Standard) is the analytical standard of Imirestat. This product is intended for research and analytical applications. Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
    Imirestat (Standard)
  • HY-N12472
    Floramanoside C
    		Inhibitor
    Floramanoside C shows 2,2-diphenyl-1-picrylhydrazyl scavenging and aldose reductase inhibitory activities.
    Floramanoside C
  • HY-W319094
    4′-Hydroxyflavone
    		Inhibitor
    4′-Hydroxyflavone (compound 50) can inhibit aldose reductase, with IC50 12 μM.
    4′-Hydroxyflavone
  • HY-155164
    WF-3681
    		Inhibitor
    WF-3681 (compound 1) is an aldose reductase inhibitor and a fungal metabolite.
    WF-3681
  • HY-N14401
    Salfredin B11
    		Inhibitor
    Salfredin B11 is an aldose reductase inhibitor.
    Salfredin B11
  • HY-W011786
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole
    		Inhibitor
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an inhibitor of larval settlement in marine organisms, demonstrating low toxicity while effectively inhibiting the metamorphosis of species such as barnacles, bryozoans, and polychaetes. 2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole also exhibits activity as an aldose reductase (ALR2) inhibitor, indicating potential therapeutic applications in diabetes-related complications.
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole
  • HY-B1202A
    Alrestatin sodium
    		Inhibitor
    Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
    Alrestatin sodium
  • HY-66009R
    Epalrestat (Standard)
    		Inhibitor
    Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
    Epalrestat (Standard)
  • HY-122177
    MK181
    		Inhibitor
    MK181 is an aldose reductase (AR) inhibitor with IC50s of 0.71 μM and 4.5 μM for aldose reductase and AKR1B10, respectively. MK181 can bind into the external loop A subpocket of AKR1B10.
    MK181
  • HY-116508
    MK 319
    		Inhibitor
    MK 319 is a selective aldose reductase (AR) inhibitor with an IC50 of 0.3 μM. MK 319 can be utilized in diabetes research.
    MK 319
  • HY-W739812
    Carboxy finasteride
    		Inhibitor
    Carboxy finasteride is a metabolite of the 5α-reductase inhibitor Finasteride (HY-13635). Finasteride is biotransformed by cytochrome P450 (CYP3A4) and is successively oxidized to Hydroxy finasteride and Carboxy finasteride. Carboxy finasteride is the major metabolite in urine, while Hydroxy finasteride is the major metabolite in plasma.
    Carboxy finasteride
  • HY-B1202R
    Alrestatin (Standard)
    		Inhibitor
    Alrestatin (Standard) is the analytical standard of Alrestatin. This product is intended for research and analytical applications. 0
    Alrestatin (Standard)
  • HY-176164
    ALR2-IN-6
    		Inhibitor
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy.
    ALR2-IN-6
  • HY-129685
    M79175
    		Inhibitor
    M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy.
    M79175
  • HY-N0310R
    Soyasaponin Bb (Standard)
    		Inhibitor
    Soyasaponin Bb (Standard) is the analytical standard of Soyasaponin Bb (HY-N0310). This product is intended for research and analytical applications. Soyasaponin Bb is an orally active, covalent inducer of heme oxygenase HO-1 and an inhibitor of aldose reductase AKR1B1. Soyasaponin Bb can regulate oxidative stress pathways, enhance antioxidant capacity, reduce reactive oxygen species (ROS) generation, and inhibit lipid peroxidation and hepatocyte apoptosis. Soyasaponin Bb improves alcohol-induced hepatocyte membrane damage and liver function abnormalities, and improves Scopolamine (HY-N0296)-induced memory impairment. Soyasaponin Bb has antioxidant, hepatoprotective, and neuroprotective activities.
    Soyasaponin Bb (Standard)
  • HY-B1392A
    Esmolol
    		Inhibitor
    Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers.
    Esmolol
Cat. No. Product Name / Synonyms Application Reactivity